Colorectal cancer is one of the most common types of cancer in Ukraine. Prognosis for patients with peritoneal carcinomatosis is unfavorable, and life expectancy is typically less than 6 months. Cytoreductive surgery was introduced as a new method of treating these patients to prolong their survival time.
The objective of the research was to evaluate and compare the efficacy of cytoreductive surgery, chemotherapy and symptomatic treatment of patients with colorectal cancer and peritoneal carcinomatosis.
Materials and methods. The research included 93 patients with colorectal cancer and peritoneal carcinomatosis. All patients were divided into 3 groups depending on the method of treatment being used after the detection of peritoneal carcinomatosis: Group I - cytoreductive surgery, Group II - palliative chemotherapy, Group III - symptomatic treatment. Cumulative overall survival in three groups was analyzed using the Kaplan-Meier method.
Results. Statistically significant difference in overall survival was observed between patients treated with different methods. The median overall survival of patients of Group I (n=44) was 15.5 months; the median overall survival of patients of Group II (n=27) was 5.9 months; in patients of Group III (n=22) it was 3.1 months (p <0.0001). The analysis of patients’ survival in Group I depending on the application of palliative chemotherapy after cytoreductive surgery showed no significant difference in overall survival: 16.5 months with chemotherapy versus 14.2 months without chemotherapy (p = 0.12).
Conclusions. Overall survival of patients with colorectal cancer and peritoneal carcinomatosis was higher when treated with cytoreductive surgery compared to palliative chemotherapy and symptomatic treatment. Palliative chemotherapy had no effect on survival after cytoreductive surgery for peritoneal carcinomatosis.
Kolesnik O, Fedorenko Z, Hulak L, Mykhaylovych Yu. Bulletin of National Cancer Registry of Ukraine № 17, Cancer in Ukraine 2014-2015. Kolesnik O, editor. Kyiv: National Cancer Institute; 2016. 146 p.
Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263-7. http://dx.doi.org/10.1200/JCO.2011.37.1039
Zubaryev M, Fetsych T, Kovaliov O, Kovaliov K, Yarema R, Revura A, et al. Efficacy of liver resection combined with chemotherapy in patients with liver metastases from colorectal cancer compared to chemotherapy alone and symptomatic treatment. Praktychna medytsyna. 2010;XVI(5):75-87.
Yarema R, Fetsych T, Glehen O, Gilly FN, Ohorchak M, Zubaryev M. Intraperitoneal disseminated cancer: the end of the era of skepticism?. Onkolohiia. 2013;15(2):88-95.
Elias D, Quenet F, Goere D. Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am. 2012;21(4):611-23. http://dx.doi.org/10.1016/j.soc.2012.07.014
Sugarbaker PH. Early intervention for treatment and prevention of colorectal carcinomatosis: a plan for individualized care. Surg Oncol Clin N Am. 2012;21(4):689-703. http://dx.doi.org/10.1016/j.soc.2012.07.009
Sugarbaker PH. Peritonectomy procedure. Ann Surg. 1995;221(1):29-42. http://dx.doi.org/10.1097/00000658-199501000-00004
Coccolini F, Gheza F, Lotti M, Virzi S, Iusco D, Ghermandi C, et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19(41):6979-6994. http://dx.doi.org/10.3748/wjg.v19.i41.6979
Elias D, Gilly FN, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63-68. http://dx.doi.org/10.1200/JCO.2009.23.9285
Klaver YLB, Simkens LHJ, Lemmens VEPP, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38(7):617-623. http://dx.doi.org/10.1016/j.ejso.2012.03.008
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.